Determinants of omalizumab dose–related efficacy in oral immunotherapy: Evidence from a cohort of 181 patients
Pauline Azzano, Maxime Paquin, Alexandra Langlois, Charles Morin, Guy Parizeault, Jonathan Lacombe‐Barrios, Kathryn Samaan, François Graham, Louis Paradis, Anne Des Roches, Philippe Bégin
Topics & Concepts
OmalizumabMedicineCohortOral immunotherapyImmunotherapyInternal medicineImmunologyImmunoglobulin EAntibodyCancerUrticaria and Related ConditionsFood Allergy and Anaphylaxis ResearchBiosimilars and Bioanalytical Methods